Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28332237 | 1.00 | MAP3K14 (0.54) | MAP3K14NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL4336968 | 1.00 | MAP3K14 (0.54) | MAP3K14NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL29653966 | 0.89 | NPC1 (0.45) | MAP3K14NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL29446210 | 0.89 | NPC1 (0.45) | MAP3K14NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL22978664 | 0.89 | NPC1 (0.45) | MAP3K14NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL22978663 | 0.89 | NPC1 (0.45) | MAP3K14NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL16499755 | 0.85 | NPC1 (0.46) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL785717 | 0.84 | KDM4E (0.41) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL785716 | 0.84 | KDM4E (0.41) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL27984676 | 0.84 | KDM4E (0.42) | MAP3K14NPC1RAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018030550-A1 | HETEROCYCLIC COMPOUNDS WITH AN ROR(GAMMA)T MODULATING ACTIVITY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-15 | — | — | WO | disclosed |
| CN-104045632-B | Antineoplastic benzodihydropyran (thiapyran) amides compound and pharmaceutically acceptable salt thereof and preparation method and application | 辽宁大学 | 2016-09-07 | — | — | CN | disclosed |
| CN-104045632-A | Antitumor drugs benzodihydropyran(thiapyran)amide compounds and pharmaceutically acceptable salts, and preparation method and application thereof | UNIV LIAONING | 2014-09-17 | — | — | CN | disclosed |
| US-7612060-B2 | Triazoles and methods of use | AMGEN INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20080249106-A1 | 3-(1-((R)-7-((4-fluoropiperidin-1-yl)methyl)-3,4-dihydro-2H-chromen-4-yl)-1H-1,2,3-triazol-4-yl)-2-(4-methylphenylsulfonamido)propanoic acid; chronic pain analgesics; side effect reduction | AMGEN INC. | 2008-10-09 | — | — | US | disclosed |
| US-7414134-B2 | B1 bradykinin receptor antagonists | AMGEN INC. (US) | 2008-08-19 | — | — | US | disclosed |
| EP-1270570-B1 | AMIDE COMPOUNDS AND USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-20060100213-A1 | Triazoles and methods of use | AMGEN INC. (US) | 2006-05-11 | — | — | US | disclosed |
| US-20060100216-A1 | Novel B1 bradykinin receptor antagonists | AMGEN INC. (US) | 2006-05-11 | — | — | US | disclosed |
| US-6933305-B2 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-08-23 | — | — | US | disclosed |
| CN-1198804-C | Amide compounds and use thereof | MITSUBISHI SEIYAKU CO LTD (JP) | 2005-04-27 | — | — | CN | disclosed |
| US-20030158413-A1 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-08-21 | — | — | US | disclosed |
| CN-1418194-A | Amide compounds and use thereof | MITSUBISHI SEIYAKU CO LTD (JP) | 2003-05-14 | — | — | CN | disclosed |
| EP-1270570-A1 | AMIDE COMPOUNDS AND USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100213-A1 | Triazoles and methods of use | CYP3A5, CYP3A43, CYP2E1 | MAP3K14 989/4885NPC1 734/4885RAB9A 3430/4885 |
| US-20030158413-A1 | Amide compounds and use thereof | ROCK2, ROCK1, RHOT2 | MAP3K14 96/4885NPC1 1207/4885RAB9A 46/4885 |
| US-20080249106-A1 | 3-(1-((R)-7-((4-fluoropiperidin-1-yl)methyl)-3,4-dihydro-2H-chromen-4-yl)-1H-1,2,3-triazol-4-yl)-2-(4-methylphenylsulfonamido)propanoic acid; chronic pain analgesics; side effect reduction | BDKRB1, BDKRB2, FPR1 | MAP3K14 704/4885NPC1 1392/4885RAB9A 3094/4885 |
| US-20060100216-A1 | Novel B1 bradykinin receptor antagonists | BDKRB1, BDKRB2, EDNRB | MAP3K14 816/4885NPC1 614/4885RAB9A 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.